NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 184 filers reported holding NEVRO CORP in Q3 2022. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $1,334,333 | +452.3% | 52,491 | +685.4% | 0.01% | +800.0% |
Q1 2023 | $241,590 | -96.9% | 6,683 | -96.6% | 0.00% | -97.8% |
Q4 2022 | $7,718,357 | +144.3% | 194,908 | +187.6% | 0.04% | +150.0% |
Q3 2022 | $3,159,000 | +6.4% | 67,781 | +0.1% | 0.02% | 0.0% |
Q2 2022 | $2,968,000 | -32.7% | 67,715 | +11.1% | 0.02% | -51.4% |
Q1 2022 | $4,410,000 | -52.8% | 60,973 | -47.1% | 0.04% | -58.4% |
Q4 2021 | $9,346,000 | +3190.8% | 115,278 | +4632.3% | 0.09% | +2125.0% |
Q3 2021 | $284,000 | -80.8% | 2,436 | -72.7% | 0.00% | -76.5% |
Q2 2021 | $1,481,000 | -69.9% | 8,936 | -74.7% | 0.02% | -73.0% |
Q1 2021 | $4,921,000 | +24.6% | 35,278 | +54.6% | 0.06% | +16.7% |
Q4 2020 | $3,950,000 | +45.2% | 22,821 | +16.8% | 0.05% | +35.0% |
Q3 2020 | $2,721,000 | -10.3% | 19,535 | -23.0% | 0.04% | -23.1% |
Q2 2020 | $3,032,000 | -2.9% | 25,376 | -4.5% | 0.05% | -8.8% |
Q4 2019 | $3,124,000 | +35.6% | 26,582 | -0.8% | 0.06% | +23.9% |
Q3 2019 | $2,304,000 | +1405.9% | 26,800 | +1034.6% | 0.05% | +1433.3% |
Q2 2019 | $153,000 | -87.3% | 2,362 | -87.8% | 0.00% | -92.3% |
Q1 2019 | $1,206,000 | -9.7% | 19,297 | -43.8% | 0.04% | -38.1% |
Q4 2018 | $1,336,000 | +402.3% | 34,358 | +635.4% | 0.06% | +320.0% |
Q3 2018 | $266,000 | +3225.0% | 4,672 | +4572.0% | 0.02% | – |
Q2 2018 | $8,000 | -69.2% | 100 | -66.7% | 0.00% | -100.0% |
Q1 2018 | $26,000 | +52.9% | 300 | +19.5% | 0.00% | +100.0% |
Q4 2017 | $17,000 | -52.8% | 251 | -37.2% | 0.00% | -50.0% |
Q3 2017 | $36,000 | -91.0% | 400 | -92.6% | 0.00% | -92.3% |
Q2 2017 | $402,000 | +219.0% | 5,400 | +300.0% | 0.03% | +188.9% |
Q1 2017 | $126,000 | +34.0% | 1,350 | +4.5% | 0.01% | +12.5% |
Q4 2016 | $94,000 | -49.7% | 1,292 | -27.9% | 0.01% | -33.3% |
Q3 2016 | $187,000 | -41.4% | 1,793 | -58.5% | 0.01% | -36.8% |
Q2 2016 | $319,000 | +192.7% | 4,319 | +122.1% | 0.02% | +216.7% |
Q1 2016 | $109,000 | +41.6% | 1,945 | +71.2% | 0.01% | +20.0% |
Q4 2015 | $77,000 | +87.8% | 1,136 | +28.9% | 0.01% | +150.0% |
Q3 2015 | $41,000 | -88.6% | 881 | -86.9% | 0.00% | -88.9% |
Q2 2015 | $361,000 | +33.2% | 6,720 | +18.8% | 0.02% | +38.5% |
Q1 2015 | $271,000 | – | 5,658 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |